PMLive20h
Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
Medical Dialogues16h
FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
Renal & Urology News18h
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
Indiatimes16h
Novartis India Share Price
Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 1,975.26 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...